These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 18237680)

  • 1. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
    Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
    J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
    Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
    J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.
    Midei MG; Coombs VJ; Lowry DR; Drossner MN; Prewitt KC; Wang JC; Loughrey MB; Gottlieb SO
    Cardiology; 2007; 107(3):172-7. PubMed ID: 16940721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Sukul D; Seth M; Schreiber T; Hanzel G; Khandelwal A; Cannon LA; Lalonde TA; Gurm HS
    J Interv Cardiol; 2017 Aug; 30(4):291-300. PubMed ID: 28543770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention.
    Coons JC; Seybert AL; Saul MI; Kirisci L; Kane-Gill SL
    Ann Pharmacother; 2005 Oct; 39(10):1621-6. PubMed ID: 16105872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile.
    Sadeghi HM; Grines CL; Chandra HR; Dixon SR; Boura JA; Dukkipati S; Harjai KJ; O'Neill WW
    J Am Coll Cardiol; 2003 Aug; 42(3):428-32. PubMed ID: 12906967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
    J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators
    Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL; Fann CS; Chang CJ
    Am J Cardiol; 2001 Mar; 87(5):537-41. PubMed ID: 11230835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
    Tornvall P; Nilsson T; Lagerqvist B
    J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute procedural complications and in-hospital events after percutaneous coronary interventions: eptifibatide versus abciximab.
    Ajani AE; Waksman R; Gruberg L; Sharma AK; Lew R; Pinnow E; Canos DA; Cheneau E; Castagna M; Satler L; Pichard A; Kent KM
    Cardiovasc Radiat Med; 2003; 4(1):12-7. PubMed ID: 12892767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.
    Raveendran G; Ting HH; Best PJ; Holmes DR; Lennon RJ; Singh M; Bell MR; Long KH; Rihal CS
    Mayo Clin Proc; 2007 Feb; 82(2):196-202. PubMed ID: 17290727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
    Racine E
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S27-36. PubMed ID: 12434712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions.
    Long KH; Ting HH; McMurtry EK; Lennon RJ; Wood DL; Holmes DR; Raveendran G; Rihal CS
    Value Health; 2008; 11(3):462-9. PubMed ID: 18489669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.